FREEHOLD, NJ--(Marketwired - Jun 29, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") would like to provide a timeline update regarding its recent 510(k) submission for its Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The company recently announced that it has completed its response to the FDA's request for more information and The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) had received and accepted the submission. In connection with our submission, we have been in close contact with the FDA reviewer and can confirm that our submission is under review and we believe we will receive a response in or around mid-July.
Commented President Bruce J. Schoengood, "We are very pleased that the Time Machine Laser 510(k) submission is under review and we believe that the anticipated response is well ahead of our initial timeline estimates. This a very exciting time for the company and we'd like to thank our shareholders for their patience and support."
In anticipation of the 510(k) approval, Medifirst is preparing for the next phase of the operation and is currently developing its sales, marketing and social media strategy for both domestic and international sales and distribution.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc. is a Nevada corporation that is headquartered in New Jersey. The company seeks innovative medical and healthcare products and technologies which are targeted to both medical and healthcare professionals, as well as everyday consumers. Medifirst is developing and establishing both consumer and professional medical cliental that can serve as a pipeline that will allow for distribution of future products and services. For more details visit www.medifirstsolutions.com for more information.
About the Lasers
Medical Lasers Manufacturer, Inc., a Nevada company, ("MLM"), a Medifirst subsidiary, will specialize in producing high quality diode-pumped solid-state lasers. The laser division, including products and treatment programs, will be operated out of MLM. The company's focus is to help patients with specific cosmetic skin conditions, as well as relief of muscle and joint pain and muscle spasm and inflammation.
Forward-Looking Statements: The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements.